Burjeel Holdings has successfully priced its inaugural USD 500 million five-year Sukuk, attracting a USD 1.6 billion orderbook, making the offering 3.2 times oversubscribed.

The Sukuk was priced at a 7.000% profit rate with a 7.125% yield, marking the lowest five-year yield by a GCC-based private non-investment-grade corporate issuer since 2020. International investors accounted for 61% of the allocation, reflecting strong confidence in the UAE’s healthcare sector and capital markets.

Click here to join our WhatsApp channel here

Rated BB+ by S&P Global Ratings and Ba2 by Moody’s, the proceeds will be used to refinance existing debt, strengthen the company’s capital structure, and support investments in advanced clinical care, research, medical education, digital transformation, and AI-powered healthcare innovation.

The Sukuk is expected to be listed on the London Stock Exchange‘s International Securities Market on 1 July 2026, subject to customary closing conditions.

Dr. Shamsheer Vayalil Chairman and CEO of Burjeel Holdings said, “The strong demand for our inaugural Sukuk reflects investor recognition of our strategy, credit fundamentals and ability to deliver sustainable growth. With the majority of demand coming from international investors, this landmark transaction demonstrates the global appeal of Burjeel’s credit story, broadens our access to international capital markets and contributes to positive momentum in the UAE and regional debt capital markets.”

Also read: Biosphere labs open inside Abu Dhabi’s HELM life sciences cluster